Evonile Pharma Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Evonile Pharma Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 16% of its market value (net cash). Higher than 96% of Healthcare companies in India.
- Steadiness Ratio: Sales grew in 1 of the last 3 years; profit grew in 1 of 3. Less steady than 94% of Healthcare companies in India.
- Debt Due Cover Ratio: Debt due within a year is covered 28.5 times by its yearly operating cash. Higher than 87% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹84Over the last 3 years, every ₹100 of reported profit came with ₹84 of operating cash.
Lower than 70% of Healthcare companies in India.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
−₹0Money owed to suppliers is larger than money owed by customers plus stock: ₹0 per ₹100 of sales comes from others' credit, against ₹2 tied up three years earlier.
Less money tied up than 87% of Healthcare companies in India.
Growth quality
Steadiness Ratio
1/3 · 1/3Sales grew in 1 of the last 3 years; profit grew in 1 of 3.
Less steady than 94% of Healthcare companies in India.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by -4% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
-4% / -0%In 3 years sales changed by -4% while total assets changed by -0%. Both moved at about the same pace.
Balance-sheet strength
Debt Due Cover Ratio
28.5×Debt due within a year is covered 28.5 times by its yearly operating cash.
Higher than 87% of Healthcare companies in India.
Cash Cushion Ratio
+16%Cash, after subtracting all debt, equals 16% of its market value (net cash).
Higher than 96% of Healthcare companies in India.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Evonile Pharma Limited owes ₹0.16 for every ₹1 it owns. Net profit fell 8% in the year to Mar 2026, and shrank 3% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
42.5Investors pay ₹42.5 for every ₹1 of Evonile Pharma Limited's yearly profit, higher than 60% of Healthcare companies in India.
P/B ratio
5.09The share price is 5.09 times Evonile Pharma Limited's book value per share, higher than 56% of Healthcare companies in India.
Market cap
₹4,159 CrThe total market value of all of Evonile Pharma Limited's shares at today's price (share price × number of shares), smaller than 54% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹818 CrWhat Evonile Pharma Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹331.23Net worth divided by the number of shares. The share price of ₹1,684 is 5.1 times this, which is the P/B above.
Return on equity (ROE)
11.9%Evonile Pharma Limited earned 11.9% on its shareholders' money over the last year, lower than 55% of Healthcare companies in India.
Owes vs Owns
0.16×Evonile Pharma Limited owes ₹0.16 for every ₹1 it owns (low), lower than 89% of Healthcare companies in India.
Dividend yield
NoneEvonile Pharma Limited does not currently pay a dividend.
Revenue growth
-1%Revenue fell 1% in the year to Mar 2026, and shrank 1% a year on average over 3 years.
Profit growth
-8%Net profit fell 8% in the year to Mar 2026, and shrank 3% a year on average over 3 years.
Profit margin
26.3%Evonile Pharma Limited keeps ₹26 of every ₹100 of revenue as net profit.
Cash quality
0.5×Cash from Evonile Pharma Limited's business was 0.5× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
74.9×Evonile Pharma Limited's operating profit covered its interest costs 74.9 times in the year to Mar 2026.
Cash vs debt
Net cashEvonile Pharma Limited held ₹654 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Evonile Pharma Limited's P/E ratio?
Investors pay ₹42.5 for every ₹1 of Evonile Pharma Limited's yearly profit, higher than 60% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Evonile Pharma Limited: ₹4,159 Cr ÷ ₹818 Cr (31 Mar 2026) = 5.1.
What is Evonile Pharma Limited's return on equity?
Evonile Pharma Limited earned 11.9% on its shareholders' money over the last year, lower than 55% of Healthcare companies in India.
How much does Evonile Pharma Limited owe compared with what it owns?
Evonile Pharma Limited owes ₹0.16 for every ₹1 it owns (low), lower than 89% of Healthcare companies in India.
Does Evonile Pharma Limited pay a dividend?
No. Evonile Pharma Limited does not currently pay a dividend.
Is Evonile Pharma Limited's revenue growing?
Revenue fell 1% in the year to Mar 2026, and shrank 1% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.